Vir Biotechnology
214 hedge funds and large institutions have $827M invested in Vir Biotechnology in 2023 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 97 increasing their positions, 51 reducing their positions, and 51 closing their positions.
90% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 51
16% more call options, than puts
Call options by funds: $1.94M | Put options by funds: $1.68M
2% less ownership
Funds ownership: 67.77% → 65.77% (-2%)
5% less funds holding
Funds holding: 226 → 214 (-12)
22% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 51
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
45% less capital inflows, than outflows
Capital inflows: $204M | Capital outflows: $371M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$26.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$25M |
| 3 |
Bridgeway Capital Management
Houston,
Texas
|
+$19.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.7M |
| 5 |
D.E. Shaw & Co
New York
|
+$11.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
-$126M |
| 2 |
Perceptive Advisors
New York
|
-$48M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$35M |
| 4 |
Paradigm Biocapital Advisors
New York
|
-$24.9M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$17.9M |
VIR Hedge Fund Activity: Q3 2023 in Review
214 of the 6,314 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q3 2023, worth a combined $827M — down 63% from $2.23B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of VIR and 40 opened new positions — a net loss of 11 holders — while 51 trimmed existing stakes and 97 added.
The largest buyer was BlackRock, adding an estimated $26.1M. The largest seller was Temasek Holdings, exiting entirely with an estimated $126M sold.
- 214 institutional investors held Vir Biotechnology (VIR) as of Q3 2023, down from 226 in Q2 2023.
- Funds reported $827M of Vir Biotechnology stock for Q3 2023, down 63% quarter-over-quarter.
- 40 funds opened new Vir Biotechnology positions in Q3 2023 and 51 closed out, a net change of -11 holders.
- The largest Vir Biotechnology buyer in Q3 2023 was BlackRock, an estimated $26.1M added.
- The largest Vir Biotechnology seller in Q3 2023 was Temasek Holdings, an estimated $126M sold.
Based on aggregated 13F filings for Q3 2023.